Celgene (NASDAQ: CELG) announced that the latest research on Otezla (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE